TP53 and breast cancer: As expected, in our breast cancer meta-dataset, incidence of ESR1 mutations is highly enriched, and of TP53 is moderately enriched, in metastatic ER+/HER2− breast cancer compared to primary (Fig. 5A) (43, 44).